HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 13 May 2013

Recent CUAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  23 papers were listed this time. Here's a few in our areas of research interest:

Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ Rev. 2013 Apr 27;3(1):11. [Epub ahead of print] PubMed PMID: 23621944.

Ferrante SA, Chhatwal J, Brass CA, et al. Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis. 2013 Apr 27;13(1):190. [Epub ahead of print] PubMed PMID: 23621902.

Wielage RC, Bansal M, Andrews JS, et al. Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective. Appl Health Econ Health Policy. 2013 Apr 25. [Epub ahead of print] PubMed PMID: 23616247.

Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer. 2013 Apr 20. [Epub ahead of print] PubMed PMID: 23611660.